Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP-VPAC2 signalling pathway.

Published in: Pharmaceutical biology (2022)

M-BYF alleviated experimental asthma by negatively regulating ILC2s and Th9 cells and the VIP-VPAC2 signalling pathway. These findings provide the theoretical basis for future research of M-BYF in asthma patient population.

Keyphrases

induced apoptosis
chronic obstructive pulmonary disease
allergic rhinitis
lung function
cell cycle arrest
oxidative stress
cell death
case report
regulatory t cells
mouse model
skeletal muscle
air pollution
high fat diet induced
preterm infants
human milk